BNR
Burning Rock Biotech LtdPrice
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- R Mar 12 Burning Rock Biotech reported stable Q4 2025 revenue of $18.1 millio…
- B Mar 31 1 insider buy $5.5M at $17.36
- R Jun 9 Burning Rock Biotech reported Q1 2026 revenue of RMB107.9M ($15.6M),…
- R Jun 9 Burning Rock reported Q1 2026 revenue of RMB107.9M ($15.6M), an 18.9…
- B Jun 11 to Jun 26 7 days of insider buys: $6.2M by 1 insider, avg $8.45
- X Jul 15 Short interest jumps 27.8% to 44.8K
Signal stack
Where each data set points today.
- InsidersBULLISH
1 insider bought $11.6M at an average $11.13. No open-market sales.
- InstitutionsBULLISH
Q2 2026: 4 added (0 new), 0 trimmed or exited.
- Short sellersSTEADY
Short interest +5.1% to 41.4K shares. 1.0 days to cover, ≈0.4% of shares.
- TrendDOWNTREND
13% below its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | ADD | $442.3K |
| MORGAN STANLEY | DOUBLED | $364.9K |
| CITADEL ADVISORS LLC | ADD | $236.6K |
| UBS Group AG | DOUBLED | $150.0K |
| MORGAN STANLEY | ADD | $246.3K |
| UBS Group AG | TRIM | $6.6K |
| BlackRock, Inc. | TRIM | $65.00 |
| MORGAN STANLEY | TRIM | $238.6K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
last action Jul 2021| Date | Firm | Rating |
|---|---|---|
| Jul 14, 2021 | CICC INITIATE | Outperform |
| Jul 13, 2020 | B of A Securities INITIATE | Buy |
| Jul 7, 2020 | Cowen & Co. INITIATE | Outperform |
Insider ledger
Form 4| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 26, 2026 | Han Yusheng Director | BUY | $199.1K |
| Jun 24, 2026 | Han Yusheng Director | BUY | $2.0M |
| Jun 23, 2026 | Han Yusheng Director | BUY | $44.9K |
| Jun 22, 2026 | Han Yusheng Director | BUY | $779.7K |
| Jun 16, 2026 | Han Yusheng Director | BUY | $1000.0K |
| Jun 12, 2026 | Han Yusheng Director | BUY | $1.9M |
| Jun 11, 2026 | Han Yusheng Director | BUY | $216.4K |
| Mar 31, 2026 | Han Yusheng Director | BUY | $5.5M |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $0.00 |
| Next Q | — | — | — | $0.00 |
| Current FY | — | — | — | $0.00 |
| Next FY | — | — | — | $0.00 |
Short side
FINRA· Sep 30, 2026SecBot reports
4 filings · 2 press releases · 0 bullish · 4 bearish- BEARISH PRESS-RELEASESep 10, 2026
Burning Rock reported Q2 2026 revenue of RMB134.7M ($19.9M), a 9.3% YoY decline, with a net loss…
Monitor NMPA approval decisions for OncoScreen BCMatch and CanCatch kits, which could drive future revenue growth. The sequential recovery from Q1 is positive but insufficient to offset the YoY…
- BEARISH 6-KSep 10, 2026
Burning Rock reported Q2 2026 revenue of RMB134.7M ($19.9M), down 9.3% YoY, with net loss widening…
Monitor regulatory milestones for OncoScreen, CanCatch, and OncoCompass kits over the next 2–4 quarters for potential revenue catalysts. The in-hospital channel growth provides a bright spot, but…
- BEARISH PRESS-RELEASEJun 9, 2026
Burning Rock Biotech reported Q1 2026 revenue of RMB107.9M ($15.6M), down 18.9% YoY, with net loss…
Monitor whether the in-hospital channel can stabilize as management cited a one-off issue at two hospitals; the pharma R&D pipeline recovery is key given the 38.6% segment decline. Cash runway of ~4…
- BEARISH 6-KJun 9, 2026
Burning Rock reported Q1 2026 revenue of RMB107.9M ($15.6M), an 18.9% YoY decline from RMB133.1M…
The accelerating revenue decline across all segments and widening net loss signal deteriorating fundamentals. With cash burn at ~RMB29M/quarter and only ~RMB449M remaining, the company has roughly…
All BNR filing & press-release reports (6)
- 6-K reportSep 10, 2026
- PRESS-RELEASE reportSep 10, 2026
- PRESS-RELEASE reportJun 9, 2026
- 6-K reportJun 9, 2026
- PRESS-RELEASE reportApr 28, 2026
- PRESS-RELEASE reportMar 12, 2026